Suppr超能文献

对重症监护病房(MICU)血小板减少患者进行颗粒免疫过滤抗血小板因子4快速检测的前瞻性观察性评估。

Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia.

作者信息

Andrews David M, Cubillos G Fernando, Paulino Sartia K, Seckinger Daniel L, Kett Daniel H

出版信息

Crit Care. 2013 Jul 22;17(4):R143. doi: 10.1186/cc12822.

Abstract

INTRODUCTION

Heparin-induced thrombocytopenia (HIT) results from antibodies to PF4/heparin complexes and clinical diagnosis is difficult. We evaluated the particle immunofiltration anti-platelet factor 4 (PIFA) rapid assay, in conjunction with a clinical risk score, in the diagnosis of HIT.

METHODS

We performed a prospective observational study in all patients admitted to the medical intensive care unit (MICU) in a large academic medical center. Patients were screened daily for thrombocytopenia defined as either a platelet count that decreased by at least 33% or an absolute platelet count less than 150,000/μL. Patients with suspected HIT underwent PIFA and ELISA testing for anti-PF4/heparin antibodies. Available residual frozen sera were sent to a reference laboratory for serotonin release assay (SRA) testing.

RESULTS

During the study period, 340 patients were admitted to the MICU, of which 143 patients met criteria for thrombocytopenia. Forty-three patients had no evidence of recent heparin exposure. PIFA and ELISA testing were performed on 100 patients, of which 92 had samples available for SRA analysis. PIFA results were negative in 62, positive in 28 and inconclusive in 2 patients. The 4Ts score showed low to intermediate risk in 57 of the PIFA negative patients. The ELISA results were negative in 86 and positive in 6 patients. SRA testing identified 3 patients with a positive SRA test and 89 patients with a negative result. All patients with a negative PIFA result also had a negative SRA result. In the one patient deemed to have clinical HIT, the pretest probability was high (4Ts score of 6) and the anti-PF4/heparin antibody testing revealed a positive SRA, inconclusive PIFA and a negative ELISA result.

CONCLUSIONS

While thrombocytopenia in our population is common, the prevalence of HIT is low. The combination of a low to intermediate pretest probability with a negative PIFA test can rapidly exclude the presence of platelet activating anti-PF4/heparin antibodies and, therefore, HIT as the cause of the thrombocytopenia. Since a positive PIFA result has a low positive predictive value, a positive PIFA is not diagnostic of HIT and additional evaluation is warranted.

摘要

引言

肝素诱导的血小板减少症(HIT)是由针对PF4/肝素复合物的抗体引起的,临床诊断困难。我们评估了颗粒免疫过滤抗血小板因子4(PIFA)快速检测法,并结合临床风险评分,用于HIT的诊断。

方法

我们在一家大型学术医疗中心的内科重症监护病房(MICU)对所有入院患者进行了一项前瞻性观察研究。每天对患者进行血小板减少症筛查,血小板减少症定义为血小板计数至少降低33%或绝对血小板计数低于150,000/μL。疑似HIT的患者接受PIFA和ELISA检测抗PF4/肝素抗体。将可用的剩余冷冻血清送至参考实验室进行血清素释放试验(SRA)检测。

结果

在研究期间,340名患者入住MICU,其中143名患者符合血小板减少症标准。43名患者近期无肝素暴露证据。对100名患者进行了PIFA和ELISA检测,其中92名患者有样本可用于SRA分析。PIFA结果阴性62例,阳性28例,2例结果不确定。4Ts评分显示,57例PIFA阴性患者为低至中度风险。ELISA结果阴性86例,阳性6例。SRA检测确定3例SRA检测阳性,89例结果阴性。所有PIFA结果阴性的患者SRA结果也为阴性。在1例被认为患有临床HIT的患者中,检测前概率较高(4Ts评分为6),抗PF4/肝素抗体检测显示SRA阳性、PIFA结果不确定、ELISA结果阴性。

结论

虽然我们研究人群中的血小板减少症很常见,但HIT的患病率较低。低至中度的检测前概率与阴性PIFA检测相结合,可以迅速排除血小板活化抗PF4/肝素抗体的存在,从而排除HIT作为血小板减少症的病因。由于阳性PIFA结果的阳性预测值较低,阳性PIFA不能诊断HIT,需要进行进一步评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a184/4056086/614b7a74c00e/cc12822-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验